SCHEMBL3402932

SCHEMBL3402932

CSC1=NC(=O)/C(=C/c2cc(Br)c(F)c(Br)c2O)S1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS1 P23219 1/20 0.50
PTGS2 P35354 1/20 0.50
KMT2A Q03164 6/20 0.45
MAPT P10636 4/20 0.45
ALDH1A1 P00352 3/20 0.45
POLB P06746 3/20 0.45
HTT P42858 2/20 0.45
GLA P06280 1/20 0.45
GAA P10253 2/20 0.44
MYC P01106 1/20 0.41
MAX P61244 1/20 0.41
MEN1 O00255 4/20 0.40
PRMT5 O14744 2/20 0.38
CGAS Q8N884 5/20 0.36
MCL1 Q07820 2/20 0.35
KDM4E B2RXH2 1/20 0.35
USP2 O75604 1/20 0.35
NSD2 O96028 1/20 0.35
SYK P43405 1/20 0.35
RECQL P46063 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3402936 1.00 PTGS1 (0.50) PTGS1PTGS2KMT2AMAPTALDH1A1
SCHEMBL3404375 0.81 PTGS1 (0.48) PTGS1PTGS2KMT2AMAPTALDH1A1
SCHEMBL3404378 0.81 PTGS1 (0.48) PTGS1PTGS2KMT2AMAPTALDH1A1
SCHEMBL4349225 0.73 KMT2A (0.51) PTGS1PTGS2KMT2AMAPTALDH1A1
SCHEMBL3425952 0.73 MAPT (0.51) PTGS1PTGS2KMT2AMAPTALDH1A1
SCHEMBL3400659 0.73 KMT2A (0.51) PTGS1PTGS2KMT2AMAPTALDH1A1
SCHEMBL3431049 0.72 KMT2A (0.50) PTGS1PTGS2KMT2AMAPTALDH1A1
SCHEMBL3431054 0.72 KMT2A (0.50) PTGS1PTGS2KMT2AMAPTALDH1A1
SCHEMBL3425364 0.72 NPC1 (0.41) KMT2AMAPTALDH1A1POLBHTT
SCHEMBL3425367 0.72 NPC1 (0.41) KMT2AMAPTALDH1A1POLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2250167-A1 ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS Chlorion Pharma, Inc. (CA) 2010-11-17 EP disclosed
US-20090275538-A1 ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS UNIVERSITE LAVAL (CA) 2009-11-05 US disclosed
US-20090275538-A1 ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS UNIVERSITE LAVAL (CA) 2009-11-05 US disclosed
US-20090275538-A1 ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS UNIVERSITE LAVAL (CA) 2009-11-05 US disclosed
WO-2009097695-A1 ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS CHLORION PHARMA, INC. (CA) 2009-08-13 WO disclosed
WO-2009097695-A1 ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS CHLORION PHARMA, INC. (CA) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275538-A1 ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS OPRL1, OPRK1, AHR PTGS1 18/4885PTGS2 12/4885KMT2A 1752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.